Combination chemotherapy for metastatic urinary bladder cancer with 5-FU, vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate.
Twenty-two patients with advanced primary bladder cancer with metastatic lesions were treated with a combination of 5-FU, vincristine, bleomycin, mitomycin, and methotrexate. Complete and partial responses were achieved in two (9%) and five (23%) patients, respectively. The overall response rate was 32%. The major toxic effects were myelosuppression and mild gastrointestinal symptoms.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage; D014529:Uridine / Q000008:administration & dosage / Q000031:analogs & derivatives; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D008937:Mitomycins; D001761:Bleomycin; C001943:5-fluorouridine; D014750:Vincristine; D003520:Cyclophosphamide; D014529:Uridine; D008727:Methotrexate